U.S. markets open in 1 hour 53 minutes

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.7800-0.2600 (-5.16%)
At close: 04:00PM EST
4.8000 +0.02 (+0.42%)
Pre-Market: 07:16AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Long-term KST

Long-term KST

Previous Close5.0400
Bid0.0000 x 800
Ask0.0000 x 1100
Day's Range4.7633 - 5.1500
52 Week Range4.7630 - 25.9000
Avg. Volume329,443
Market Cap89.94M
Beta (5Y Monthly)-0.03
PE Ratio (TTM)N/A
EPS (TTM)-1.7620
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NOVN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novan, Inc.
    EGRX: Lowering target price to $42.00EAGLE PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $42.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    7 months agoArgus Research
View more
  • GlobeNewswire

    Novan to Participate in the Virtual Investor Roundtable Event

    – Live moderated video webcast discussion among management and Pediatric Dermatology Thought Leader on Wednesday, November 17th at 1:00 PM ET – DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, joined by a pediatric dermatology thought leader, will participate in the Virtual Investor Roundtable Event on Wednesday, November 17, 2021 at 1:00 PM ET.As part

  • Zacks Small Cap Research

    NOVN: KINSOLUS: A Solution for Molluscum

    By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT Third Quarter 2021 Results On November 10, 2021, Novan Inc. (NASDAQ:NOVN) reported third quarter financial results in a press release concurrent with the filing of Form 10-Q . A conference call and webcast was also held to update investors on financial and operational results. Most recently, the FDA conditionally accepted

  • GlobeNewswire

    Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results

    – Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – – Advancing priority development pipeline assets by progressing SB019, for the treatment of SARS-CoV-2, toward a Phase 1 study in 2022, and SB204, for the treatment of acne vulgaris, toward a registrational Phase 3 study in 2023 – – Company to host update conference call and webcast today at 8:30 a.m. ET